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Cysteamine inhibits lysosomal oxidation of low density lipoprotein
in human macrophages and reduces atherosclerosis in mice
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H I G H L I G H T S
• The drug cysteamine, which accumulates in lysosomes, inhibited the oxidation of LDL by iron at pH 4.5 (the pH of lysosomes).• Cysteamine inhibited the lysosomal oxidation of LDL inside cultured macrophages.• Cysteamine reduced atherosclerosis in LDL receptor knockout mice.• These results support our hypothesis that lysosomal oxidation of LDL is important in atherosclerosis.• Antioxidant drugs that concentrate in lysosomes might provide a novel therapy for this disease.
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A B S T R A C T
Background and aims: We have shown previously that low density lipoprotein (LDL) aggregated by vortexing is
internalised by macrophages and oxidised by iron in lysosomes to form the advanced lipid/protein oxidation
product ceroid. We have now used sphingomyelinase-aggregated LDL, a more pathophysiological form of ag-
gregated LDL, to study lysosomal oxidation of LDL and its inhibition by antioxidants, including cysteamine (2-
aminoethanethiol), which concentrates in lysosomes by several orders of magnitude. We have also investigated
the effect of cysteamine on atherosclerosis in mice.
Methods: LDL was incubated with sphingomyelinase, which increased its average particle diameter from 26 to
170 nm, and was then incubated for up to 7 days with human monocyte-derived macrophages. LDL receptor-
deficient mice were fed a Western diet (19–22 per group) and some given cysteamine in their drinking water at a
dose equivalent to that used in cystinosis patients. The extent of atherosclerosis in the aortic root and the rest of
the aorta was measured.
Results: Confocal microscopy revealed lipid accumulation in lysosomes in the cultured macrophages. Large
amounts of ceroid were produced, which colocalised with the lysosomal marker LAMP2. The antioxidants cy-
steamine, butylated hydroxytoluene, amifostine and its active metabolite WR-1065, inhibited the production of
ceroid. Cysteamine at concentrations well below those expected to be present in lysosomes inhibited the oxi-
dation of LDL by iron ions at lysosomal pH (pH 4.5) for prolonged periods. Finally, we showed that the extent of
atherosclerotic lesions in the aortic root and arch of mice was significantly reduced by cysteamine.
Conclusions: These results support our hypothesis that lysosomal oxidation of LDL is important in atherosclerosis
and hence antioxidant drugs that concentrate in lysosomes might provide a novel therapy for this disease.
1. Introduction
Oxidised LDL was at one time widely believed to be important in the
pathogenesis of atherosclerosis [1,2], the underlying cause of the large
majority of myocardial infarctions and thrombotic strokes. This was
because oxidised LDL has numerous potential pro-atherosclerotic
effects. For example, even small amounts of oxidised lipids from mildly-
oxidised (also called minimally-modified) LDL can activate genes for
cellular adhesion molecules and chemotactic proteins [3], thus gen-
erating an inflammatory response. More highly oxidised LDL can de-
crease the mobility of macrophages [4], induce apoptosis [5] or ne-
croptosis [6], increase or decrease autophagy [7] and activate the
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NLRP3 inflammasome [8], amongst other effects. Oxidised LDL in-
creases the production of metalloproteinases [9], which destabilise the
fibrous caps over advanced lesions causing thrombosis.
The oxidised LDL hypothesis proposes that cells in the arterial wall
oxidise LDL in the extracellular space and then take it up rapidly,
leading to the formation of foam cells which are characteristic of
atherosclerosis [1]. Oxidised LDL has been detected in animal and
human atherosclerotic lesions by immunohistochemistry [10–12]. De-
spite intensive research focusing on this hypothesis for decades, the
underlying mechanisms by which LDL is oxidised in the arterial intima
remain uncertain. Two key problems with this conventional view are
that oxidation is inhibited by low concentrations of interstitial fluid or
serum (components of which enter the wall) [13,14] and that large
clinical trials have failed to show that antioxidants protect against
cardiovascular disease [15].
To account for these problems, we hypothesised that LDL non-
oxidatively modified and aggregated by enzymes, such as sphingo-
myelinase [16], proteases [17] or secretory phospholipase A2 enzymes
[18], in the extracellular space of atherosclerotic lesions [19] is rapidly
endocytosed by macrophages and delivered to lysosomes, where it
might be oxidised [20]. In support of this view, we showed that 7 days
after taking up mechanically-aggregated (vortexed) LDL, mouse J774
macrophage-like cells and human monocyte-derived macrophages
(HMDM) generated ceroid in their lysosomes. Ceroid (lipofuscin) is a
final product of lipid oxidation that consists of insoluble polymerised
lipid and protein complexes and it is found within foam cells in
atherosclerotic lesions [21]. Furthermore, 7-ketocholesterol, one of the
main products of LDL oxidation, was detected by HPLC after J774 cells
were treated with acetylated LDL, which is also rapidly endocytosed.
Chloroquine, a weak base that concentrates in lysosomes and increases
their pH, inhibited the oxidation of LDL, consistent with lysosomes
being the critical intracellular organelle [20].
We further proposed that the oxidation in lysosomes is mediated by
iron [20]. It is known that foam cells in human atherosclerotic lesions
contain catalytically active iron in their lysosomes [22,23]. We have
demonstrated that iron [20,24,25] or ferritin [26] can oxidise LDL ef-
fectively at the lysosomal pH of 4.5 (but not at pH 7.4), as measured by
spectrophotometry and the iron chelator desferrioxamine, which is pi-
nocytosed by cells and delivered to lysosomes, inhibited LDL oxidation
in the experiments described above [20]. The oxidation of LDL by iron
at acidic pH is inhibited by cysteamine (2-aminoethanethiol) [27], an
antioxidant that accumulates in lysosomes [28]. The lysosomal oxida-
tion of LDL in the lysosomes of macrophages increases their pH and
causes the secretion of inflammatory cytokines, both of which are de-
creased by cysteamine [27].
Collectively, these findings support our explanation of how LDL is
oxidised in atherosclerotic lesions despite the presence of numerous
antioxidants in interstitial fluid. They also suggest why large clinical
trials have shown no protection against cardiovascular disease by an-
tioxidants [15], as most antioxidants do not have ready access to ly-
sosomes. The antioxidant α-tocopherol (vitamin E) is contained within
LDL and would therefore be delivered to lysosomes with LDL, but we
have shown that α-tocopherol in LDL does not inhibit LDL oxidation at
acidic pH as effectively as it does at pH 7.4 [24]. The antioxidant
probucol does not inhibit the initial oxidation of LDL by iron at lyso-
somal pH [25]. Importantly, our findings suggest new ways of in-
hibiting the disease process.
Our original experiments used LDL that had been aggregated by
vortexing or modified by acetylation, rather than by components of the
arterial wall, however, and they were only conducted in vitro [20].
Sphingomyelin is one of the phospholipids present in LDL. Sphingo-
myelinase is a sphingomyelin-specific form of phospholipase C, which
hydrolyses the phosphodiester bond of sphingomyelin to generate cer-
amide and phosphocholine [16]. Ceramide is hydrophobic and causes
the aggregation of LDL particles [29], but interactions between newly
exposed segments of apolipoprotein B-100 may also be involved [30].
Sphingomyelinase can be secreted by macrophages and endothelial
cells [31] and is active in the arterial wall [32], with increased sphin-
gomyelinase activity in atherosclerotic lesions compared to normal
arteries [33]. Sphingomyelinase greatly enhances subendothelial LDL
retention in atherosclerotic lesions and increases lesion development
[34]. The levels of ceramide are significantly elevated in atherosclerotic
lesions and LDL isolated from these lesions [32,33,35].
Here we show that LDL aggregated by sphingomyelinase (SMase-
LDL), a more pathophysiological form of modified LDL than vortexed or
acetylated LDL, is rapidly taken up and oxidised in the lysosomes of
human macrophages. We also report the effects of cysteamine and other
antioxidants on this oxidation. We examined the effects of cysteamine
not only on cell-free and cell-mediated oxidation in vitro, but also in an
in vivo animal model of atherosclerosis in which LDL is raised.
2. Materials and methods
2.1. Chemicals and reagents
Chemicals and reagents were purchased from Sigma-Aldrich,
Dorset, UK, or Fisher Scientific Ltd, Loughborough, UK, unless other-
wise stated. Solutions were prepared using ultrapure water generated
from a Barnstead Nanopure system. Cell culture media and serum were
obtained from Life Technologies Ltd (Invitrogen, Paisley, UK).
Amifostine and 2-[(3-aminopropyl) amino] ethanethiol dihy-
drochloride (WR-1065) were kindly supplied by the National Institute
of Health, National Cancer Institute, Bethesda, Maryland, USA. Organic
solvents were HPLC or molecular biology grades.
2.2. Aggregation of LDL with sphingomyelinase
Native LDL (1.019–1.063 g/ml) was isolated from plasma of healthy
volunteers by sequential density ultracentrifugation [36]. Native LDL
was diluted to 2mg protein/ml with a buffer containing NaCl
(150mM), MgCl2 (10mM) and HEPES (5mM), pH 7.4 and incubated
with sphingomyelinase from Bacillus cereus (Sigma, catalogue number
S9396–25UN) at 10 mU/ml, as described by Walters and Wrenn
[29,37], until the attenuance (absorbance plus light scattering) at
680 nm in a spectrophotometer, as a measure of LDL aggregation [38],
increased from 0.0017 ± 0.0005 to 0.027 ± 0.005 (mean ± SEM of
4 independent experiments). Sphingomyelinase aggregated-LDL
(SMase-LDL) was dialysed against phosphate buffer (140mM NaCl,
8.1 mM Na2HPO4, 1.9mM NaH2PO4 and 100 μM EDTA), pH 7.4 (which
had been pre-treated with washed Chelex-100 to remove contaminating
transition metals) and sterilised with a 0.45 μm Minisart filter before
adding to the cell culture. Aggregation was confirmed by dynamic light
scattering in UV grade cuvettes with a Zetasizer Nano Series particle
sizer (Malvern Instruments, Worcestershire, UK).
2.3. Measurement of hydroperoxides
Hydroperoxides in LDL were measured by a tri-iodide assay [39].
2.4. Spectrophotometric measurements of LDL oxidation by iron
Native LDL (50 μg protein/ml) was incubated with FeSO4 (5 μM) at
pH 4.5 (150mM NaCl/10mM sodium acetate buffer) at 37 °C in an
automated spectrophotometer and the attenuance against reference
cuvettes was monitored at 234 nm [24,40].
2.5. Cell culture
Human macrophages or THP-1 cells were cultured under humidified
95% air/5% CO2 at 37 °C in Gibco RPMI 1640 containing L-glutamine
(0.3 g/l), penicillin (50 IU/ml), streptomycin (50 μg/ml), amphotericin
B (0.95 μg/ml) and human or fetal bovine serum (10%, v/v),
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respectively, unless otherwise stated. THP-1 cells were purchased from
the European Collection of Cell Cultures (Salisbury, UK). The THP-
1 cells were differentiated into macrophages on 18× 18mm class
coverslips in 6-well tissue culture plates using phorbol 12-myristate 13-
acetate (25 ng/ml) over 3 days prior to experiments. Human monocyte-
derived macrophages (HMDM) were prepared from blood donated by
healthy adults using Lymphoprep™ density gradient solution (Axis-
Shield, Oslo, Norway) as previously described [41]. Briefly, after se-
paration from blood cells, monocytes were incubated in RPMI medium
without serum in nonadherent 6-well tissue culture plates for 40 h, then
transferred to RPMI with 10% (v/v) human serum in ordinary 6-well
tissue culture plates for 10–14 days, with granulocyte macrophage
colony-stimulating factor (25 ng/ml) present for just the first 3–4 days.
The medium was changed every 3–4 days. Before use, the HMDM were
removed with trypsin (0.25%) and cell scrapers and transferred on to
coverslips at 5× 106 cells/ml. The suspension of THP-1 cells contained
1.5×105 cells/ml. Lipoprotein-deficient serum (LPDS) was prepared
by ultracentrifugation at 115 000 g and 4 °C for 48 h at the density of
1.25 g/ml.
2.6. Detection and quantification of ceroid in macrophages
HMDM cultured on glass coverslips were incubated in medium
containing either SMase-LDL or native LDL at 200 μg protein/ml, or
without LDL, for 24 h. The medium was washed off 3 times with warm
PBS and the incubation was continued for 7 days with RPMI 1640
medium containing 10% (v/v) lipoprotein-deficient serum (LPDS). The
medium was changed every 2 days. To study effects of antioxidants,
butylated hydroxytoluene (BHT; freshly dissolved in ethanol), amifos-
tine or WR-1065 (both freshly dissolved in nanopure water), were
added to the cells every day after the LDL was washed off. To demon-
strate ceroid, cells on coverslips were fixed with 4% (w/v) paraf-
ormaldehyde in PBS, treated with ethanol and xylene for 5min each to
remove ‘soluble lipids’ and stained with Oil Red O. Staining was de-
tected using a transmitted-light microscope equipped with a digital
camera (Axioskop 2, Carl Zeiss Ltd). It was quantified with ImageJ 1.46
(National Institute of Mental Health, Bethesda, Maryland, USA) by
calculating the average intensity of red pixels in five randomly posi-
tioned digital images containing a total of at least 100 cells on each
slide.
2.7. Colocalisation of intracellular lipids or ceroid with lysosomes
HMDM were incubated with SMase-LDL for either 24 h to demon-
strate the lysosomal localisation of lipids or incubated for an additional
7 days in the absence of lipoproteins, as described above, to show the
colocalisation of ceroid and lysosomes. After incubation with SMase-
LDL, cells were washed and fixed with 4% (w/v) paraformaldehyde in
PBS (pH 7.4). Lysosomes were incubated with rabbit polyclonal IgG
anti-lysosomal associated membrane protein 2 antibody (anti-LAMP2
antibody, Santa Cruz Biotechnology Inc, Dallas, Texas, USA; catalogue
number H207) at 200 μg/ml overnight at 4 °C, followed by incubation
with Alexa Fluor 488-conjugated donkey anti-rabbit IgG (Invitrogen;
catalogue number A-21206) as the secondary antibody for 1 h at room
temperature. Intracellular lipids were stained with LipidTOX™ Red
(Invitrogen) for 30min at room temperature. Fluorescence was de-
tected with a confocal microscope (Leica DMIRE2) using sequential
acquisition. Excitation wavelengths of 488 nm and 594 nm were used
for lysosomes and lipids, including ceroid, respectively. Lysosomal
ceroid was examined after treatment with ethanol and xylene, to re-
move the ‘soluble lipids’.
2.8. HPLC analysis
Cholesterol and cholesteryl esters were quantified by reverse-phase
HPLC. Lipids were extracted from macrophages using methanol and
hexane [42]. The upper hexane layer was collected and evaporated at
ambient temperature in a SpeedVac Concentrator System (Thermo-
Fisher). The residue was redissolved in the mobile phase (acetonitrile/
propan-2-ol (30/70, v/v)) and injected into a C18 column in an HPLC
(PerkinElmer 200 series) [42]. Cholesterol and cholesteryl esters were
detected at 210 nm. The identities of the peaks were confirmed by mass
spectrometry (results not shown) and quantified using standards of pure
chemicals from Sigma.
Cysteamine in mouse plasma samples cells was measured using 7-
fluorobenzo-2-oxa-1,3-diazole-4-sulfonate by reverse-phase HPLC with
a C18 column and a fluorescent detector [43]. Tri-n-butylphosphine
was used to release protein-bound thiols and reduce oxidised thiols.
2.9. Animal experiments
All procedures complied with the Animals (Scientific Procedures)
Act 1986 and were approved by the Ethical Review Process Committee
of Imperial College London. Ten week-old LDL receptor-knockout
(LDLr−/−) female mice (Charles River, Margate, UK) were fed normal
laboratory chow for a week and then a cholate-free high fat diet (Diet
W, SDS, Horley, Surrey, UK) containing cocoa butter (15%, w/w) and
cholesterol (0.25%, w/w) for 12 weeks. Animals (n= 19–22 per group)
received cysteamine hydrochloride at 2.2 and 8.8 mM in purified
drinking water of electrical resistivity 15MΩ-cm (equivalent to 42mg
of the free base/kg body weight/day and 170mg/kg body weight/day,
assuming 20 g mice drink 5ml of water per day [44]) or purified
drinking water as a control. Water was changed daily. At the end of the
trial, mice were weighed and killed by pentobarbital overdose (20mg
ip). Blood was taken by cardiac puncture with EDTA as the antic-
oagulant, the chest cavity was cut open to expose the heart and 10ml of
PBS was perfused through the circulatory system via the left ventricle,
draining through a cut in the right atrium. The animals were then
stored in 2% (w/v) paraformaldehyde in NaCl (150mM) at 4 °C for
≥48 h before dissection. Blood samples were centrifuged and plasma
aliquots were stored at −80 °C before measurement of cysteamine by
HPLC [43] and lipid profile with an ILab600 chemical analyser using
kits supplied by Instrumentation Laboratory [45].
2.10. Lesion measurement
The heart, aortic root, aortic arch and descending aorta were dis-
sected as previously described [46,47]. The specimens were coded and
analysed blindly regarding the treatment groups. The hearts were em-
bedded in gelatin and frozen in OCT embedding medium. The aortic
root was serially sectioned at 10 μm from where the aortic sinus ap-
peared until the point where valve bases were shrunken, but still
visible. Four sections per slide were saved, resulting in a total of 20
slides saved. Every other slide was stained with Oil Red O, Harris
haematoxylin and Light Green, as described by Baglione and Smith
[48]. The aortic segment from the arch to the iliac bifurcation was cut
open under a dissecting microscope, pinned to a silicone elastomer
(Sylgard 184, Dow Corning) in a Petri dish and stained with Oil Red O.
Images were acquired with a digital camera fitted to a dissecting mi-
croscope. Lesions were quantified by drawing around the digital images
using ImageJ and measuring their areas, using a scale with a known
distance. Their extent was expressed as μm2 cross sectional area in the
aortic root and per cent en face area covered by lesions in the aortic arch
and in the rest of the thoracic plus abdominal aorta. The lesion area in
the aortic root of each mouse was calculated as the mean for the ten
slides that were quantified.
2.11. Statistical analysis
Data are presented as mean ± SEM of at least 3 independent ex-
periments or of 19–22 mice within each group. Comparisons between
control and treated samples were analysed by one-way-ANOVA with
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Dunnett's or Tukey's post hoc tests or, where appropriate, by t-tests.
Differences were considered significant at p < 0.05.
3. Results
3.1. Aggregation of LDL by sphingomyelinase
Incubation of native LDL with sphingomyelinase for 4 h at 37 °C
increased the LDL particle diameter from 26 ± 2 nm to 170 ± 28 nm
(Supplementary Fig. 1A). The increase in LDL particle size caused an
increase in light scattering at 680 nm, as monitored in a spectro-
photometer (Supplementary Fig. 1B). Although the particle size might
continue to increase with time, the optimal average LDL particle dia-
meter was considered to be about 200 nm, as larger particles may be
lost when sterilising with a 0.45 μm filter. No hydroperoxides were
detected by a tri-iodide assay in SMase-LDL (or native LDL) in two in-
dependent experiments. In another experiment, the hydroperoxides in
SMase-LDL were 7.8 nmol/mg protein (and were undetectable in native
LDL). This was only about 1% of the maximum levels found in oxidised
LDL [49]. LDL aggregation by sphingomyelinase was not affected by
cysteamine (see below) (Supplementary Fig. 2).
3.2. Accumulation of LDL in lysosomes in macrophages
Incubation with SMase-LDL for 4 h caused substantial lipid-accu-
mulation in THP-1 macrophages-like cells, with SMase-LDL causing
significantly more lipid accumulation than native LDL (Fig. 1A–D).
Intracellular lipids colocalised with lysosomes labelled with anti-
LAMP2 antibody in HMDM (Fig. 1E–G).
HPLC [42,50] showed that THP-1 cells incubated with SMase-LDL
for 24 h had greatly increased levels of cholesteryl linoleate and pal-
mitate (Supplementary Table 1). These lipids were very low or absent in
control cells. Nonesterified cholesterol doubled in cells incubated with
SMase-LDL.
Fig. 1. Lipids from SMase-LDL rapidly ac-
cumulate in human macrophages and colo-
calise with lysosomes.
THP-1 macrophage-like cells and HMDM
cells were incubated with SMase-LDL
(200 μg protein/ml) for 4 or 24 h, respec-
tively. The uptake of aggregated LDL by
cells was detected by Oil Red O staining and
transmitted-light microscopy. THP-1 mac-
rophages were incubated (A) alone, (B) with
native LDL or (C) SMase-LDL. Scale bar:
30 μm. (D) Intracellular lipids in THP-1
macrophage-like cells, measured as in-
tensity of red pixels, were quantified using
ImageJ. Mean ± SEM of 3 independent
experiments. p <0.001 ANOVA; followed
by Tukey's post-hoc test, *p < 0.01 com-
pared to others. Lysosomes in HMDM were
labelled with anti-LAMP2 antibody (E)
whilst intracellular lipids were stained with
LipidTOX™ Red (F). Their colocalisation
appeared yellow in an overlaid confocal
image (G). Scale bar: 30 μm.
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3.3. Ceroid formed in lysosomes of macrophages
HMDM or THP-1 macrophage-like cells were cultured in RPMI
containing human serum alone or also containing native or SMase-LDL
for 24 h and were washed and incubated for 7 days in the complete
absence of lipoproteins. The lipid content of THP-1 cells was increased
in a concentration-dependent manner by SMase-LDL, as shown by Oil
Red 0 staining (Supplementary Fig. 3). The cells were incubated in the
absence of lipoproteins during the 7-day ‘chase’ period to exclude the
possibility that lipoproteins are oxidised in the medium during this time
and taken up by the cells. Any oxidation of lipoproteins would therefore
have to be intracellular. Ceroid was clearly visible in HMDM in the form
of Oil Red O stained, irregularly shaped granules in cells treated with
SMase-LDL after other lipids had been removed by organic solvents
[21] (Fig. 2C). No significant ceroid was present in cells that had been
incubated without LDL (Fig. 2A) or with native LDL (Fig. 2B). Li-
pidTOX™ Red stained ceroid colocalised with anti-LAMP2-labelled ly-
sosomes in cells incubated with SMase-LDL (Fig. 2D–F). Ceroid was also
present in THP-1 cells incubated under similar conditions
(Supplementary Fig. 4).
We next investigated the effects of selected lipophilic and hydro-
philic antioxidants on lysosomal LDL oxidation. Lysosomal lipid accu-
mulation was induced in HMDM using SMase-LDL, which was then
washed off and the incubation continued for 7 days in the complete
absence of lipoproteins but in the presence of the lipophilic antioxidant
BHT and the hydrophilic prodrug amifostine, which is converted by
alkaline phosphatase in vivo into the antioxidant WR-1065. The struc-
tures of these antioxidants are shown in Supplementary Fig. 5. All these
compounds inhibited ceroid formation in HMDM considerably
(Fig. 2G).
3.4. LDL oxidation by iron at lysosomal pH is inhibited by cysteamine
We explored in more detail the effects of the lysosomotropic drug
cysteamine (structure given in Supplementary Fig. 5). Cysteamine in-
hibited the oxidation of LDL greatly and in a concentration-dependent
manner when LDL was incubated with FeSO4 in a spectrophotometer at
the lysosomal pH of 4.5 (Fig. 3A). The lag phase increased from about
Fig. 2. Human macrophages incubated with SMase-
LDL generate lysosomal ceroid.
HMDM cells were incubated without LDL (A), with
native LDL (B) or SMase-LDL (C) (200 μg protein/ml)
in 45% RPMI medium and 45% buffer (10mM
MgCl2, 5 mM HEPES and 150 mM NaCl, pH 7.4) with
10% (v/v) human serum for 24 h. The cells were
then cultured for a further 7 days in RPMI with 10%
(v/v) LPDS. The cells were stained for ceroid (A, B
and C). Scale bar: 30 μm. Colocalisation of ceroid
and lysosomes was observed by confocal microscopy
for cells incubated with SMase-LDL. (D) Lysosomes
were labelled with an anti-LAMP2 antibody, (E)
ceroid was stained with LipidTOX™ Red and (F) an
overlaid image is shown. Scale bar: 30 μm. HMDM
were incubated with SMase-LDL (200 μg protein/ml)
for 24 h. They were then incubated for a further 7
days in the absence of lipoproteins in RPMI with 10%
(v/v) LPDS, but in the presence of BHT (10 μM),
amifostine (100 μM) or WR-1065 (100 μM). Cells
were also incubated without LDL or antioxidants.
The ceroid levels in the cells were quantified using
ImageJ to show inhibition by BHT, amifostine and
WR-1065. Mean ± SEM of 3 independent experi-
ments. *p < 0.001, ANOVA and post-hoc Dunnett's
test compared to SMase-LDL with no antioxidant.
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1 h to over 30 h when 250 μM cysteamine was added. Cysteamine
added to cultured HMDM at a concentration of 1 μM or over inhibited
ceroid production by≥80% (Fig. 3B and C).
3.5. Atherosclerosis in mice is inhibited by cysteamine
We next investigated the effect of cysteamine on atherosclerosis in
LDL receptor-deficient mice fed an atherogenic diet. Two doses were
used: one equivalent to that received by patients with cystinosis (42mg
free cysteamine base per kg body weight per day [51]), assuming the
mice drank 5ml of water per day [44], and a higher one in case the
human dose was ineffective.
As cysteamine might be oxidised in solution, we assessed its stability
in the drinking water supplied to the mice, which was purified water
with a high resistivity (15MΩ-cm), using a HPLC assay. There was a
54% and 53% loss of free cysteamine for the lower (2.2 mM) and higher
doses (8.8mM), respectively, after 24 h. We also assessed the ability of
cysteamine solutions to retain their ability to inhibit the oxidation of
LDL by iron. Cysteamine (10mM) was left in the drinking water used
for the mice (15MΩ-cm) or ultrapure water (18.2MΩ-cm) at room
Fig. 3. Cysteamine inhibits LDL oxidation by iron at
pH 4.5 and ceroid formation in macrophages.
(A) LDL (50 μg of protein/ml) in NaCl/sodium
acetate buffer (pH 4.5) was incubated with 5 μM
FeSO4 at 37 °C in quartz cuvettes. Cysteamine (final
concentrations 25, 50 and 250 μM) was added to the
cuvettes at the start of the incubation. Oxidation and
UV scattering were monitored by measuring the
change in attenuance (absorbance plus UV scat-
tering) at 234 nm against appropriate reference cuv-
ettes. The stages of oxidation are marked with ar-
rows: 1, lag phase; 2, rapid oxidation phase; 3, slow
oxidation phase; 4, aggregation phase and 5, sedi-
mentation phase. These data are representative of
three independent experiments. Cysteamine at 25 μM
increased the time required to increase the attenu-
ance to 0.1 by 5.5 ± 1.5 fold (p < 0.05) and at
50 μM by 14.4 ± 1.2 fold (p < 0.001),
mean ± SEM of 3 independent experiments; ANOVA
and Dunnett's post-hoc test. (B) Human monocyte-
derived macrophages were cultured on coverslips
and incubated with SMase-LDL at 200 μg protein/ml
for 24 h. They were washed and cultured for 7 days
with RPMI 1640 medium containing 10% (v/v)
human lipoprotein-deficient serum to which cystea-
mine was added every 24 h. The cells were then
washed, fixed, treated with ethanol and xylene to
remove non-ceroid lipids and stained for ceroid with
Oil Red O. Ceroid was quantified using ImageJ. (C)
Mean ± SEM of 4 independent experiments.
*p <0.001, ANOVA and Dunnett's post hoc test.
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temperature for 48 h. When diluted 200 fold, it was still able to inhibit
the oxidation of LDL by 5 μM FeSO4 at pH 4.5, but it was, respectively,
69 ± 3% and 34 ± 2% (mean ± SEM of three experiments) less ef-
fective than freshly made solutions at prolonging the lag phase. There
would therefore have been some loss of cysteamine activity in the
drinking water the mice received, which was changed every day, but
most of the cysteamine should have remained intact.
No differences were observed among the control and cysteamine
groups for body weight and plasma lipid and lipoprotein concentrations
(Table 1).
The inhibition of disease by the lower and higher doses was, re-
spectively, 18.4% and 18.5% in the root, 25.5% and 22.7% in the arch
and 33.3% and 40.7% in the remaining thoracic plus abdominal aorta
(Table 1). Lesion areas for the individual mice and representative
images of aortic arches from the control and cysteamine groups are
shown in Fig. 4. The reductions were not significantly affected by dose
at any of the three aortic locations, as assessed by 2-way ANOVA
(p=0.65) or t-test (p=0.93 for aortic root, p=0.57 for aortic arch
and p=0.69 for the remaining thoracic plus abdominal aorta)
(Table 1). The data for the two doses were therefore combined for
further statistical analysis. The effect of cysteamine was significant in
both the aortic root (p=0.010; t-test) and arch (p=0.00001; t-test).
Cysteamine appeared to cause a greater reduction in the remaining
thoracic and abdominal aorta, but the effect only approached statistical
significance (p=0.11; t-test), probably because the level of disease was
low in this region (coverage averaging only around 2%) and the mea-
surements were consequently highly variable (the coefficient of varia-
tion was 79%, compared to 20% in the root and 17% in the arch).
There were low, but detectable, concentrations of cysteamine in the
plasma of control mice (Table 1). This is expected because cysteamine is
generated in animals as part of the coenzyme A catabolic pathway [52].
The cysteamine concentrations were significantly higher in mice re-
ceiving the drug, with higher concentrations in the higher dose group.
Our lower and higher dose treatments appeared to result in plasma
cysteamine levels much below those reported for humans. The plasma
cysteamine concentrations are around 40 μM in patients on oral cy-
steamine [53]. This discrepancy may be an artefact arising from the
nocturnal feeding habits of mice. Cysteamine has a short half-life; about
2 h in humans [54] and 0.5 h in mice [55]. The blood of the mice was
taken in the mid-morning when plasma concentrations would have
fallen considerably. Even these concentrations are expected to inhibit
the lysosomal oxidation of LDL in macrophages considerably (Fig. 3C).
4. Discussion
We previously reported that LDL acetylated to increase its net ne-
gative charge or aggregated by vortexing is taken up rapidly by mac-
rophages and oxidised in lysosomes [20]. Here we describe experiments
carried out with LDL aggregated (but not oxidised) by sphingomyeli-
nase, a more pathophysiological approach to study the lysosomal oxi-
dation of LDL, as sphingomyelinase is present in atherosclerotic lesions
and may be one of the key enzymes causing the aggregation of LDL in
the extracellular space of atherosclerotic lesions [34]. The susceptibility
of LDL to sphingomyelinase-induced aggregation predicts future cor-
onary heart disease deaths [56]. We found that incubation of LDL with
sphingomyelinase increased the LDL particle size from 26 nm to 170 nm
(Supplemental Fig. 1). Lipid accumulation in macrophages was in-
creased greatly by SMase-LDL as shown by Oil Red O staining
(Fig. 1A–D) and by HPLC (Supplementary Table 1). The levels of non-
esterified cholesterol, cholesteryl linoleate and cholesteryl palmitate,
were increased in macrophages incubated with SMase-LDL
(Supplementary Table 1). The much higher levels of cholesteryl li-
noleate compared to cholesteryl oleate is consistent with the lipid being
mainly lysosomal, as the main cholesteryl ester in LDL is cholesteryl
linoleate whereas the main cholesteryl ester in cytosolic lipid droplets is
cholesteryl oleate [57]. The lipids were localised in lysosomes as shown
by confocal microscopy (Fig. 1E–G). Aggregated LDL (produced by
vortexing) has been shown to be degraded in extracellular compart-
ments on the surface of macrophages (lysosomal synapses), which
contain regions of acidity [58,59], but most of our aggregated LDL was
transported to lysosomes.
Importantly, LDL aggregated by sphingomyelinase oxidised to form
the advanced oxidation product ceroid in lysosomes of macrophages.
Ceroid is a final product of lipid oxidation that consists of insoluble
polymerised lipids and proteins and is found within foam cells in
human atherosclerotic lesions [21]. Ceroid is formed in lysosomes by an
iron-catalysed oxidative process and its production can be diminished
by antioxidants or iron chelators [20,25,60]. It can be detected as Oil
Red O-stained lipid after other lipids have been removed by organic
solvents [21]. The colocalisation study (Fig. 2D–F) showed clearly that
lysosomes contained ceroid generated from internalised LDL. Lyso-
somes contain catalytically active iron [22] and iron staining is
common in human advanced atherosclerotic lesions and colocalises
with ceroid [23]. This iron may be derived either by autophagy of or-
ganelles, together with their iron-containing proteins, or from the en-
docytosis of iron-containing proteins [61].
Table 1
Effect of cysteamine on atherosclerosis in LDL receptor knockout mice.
Control (n= 19) Cysteamine (2.2 mM in drinking water) (n= 21) Cysteamine (8.8 mM in drinking water) (n= 22)
Weight (g) 22.4 ± 0.6 22.3 ± 0.4 22.8 ± 0.7
Cholesterol (mM) 39.9 ± 2.5 40.3 ± 1.5 38.8 ± 1.9
Triacylglycerol (mM) 4.64 ± 0.31 4.67 ± 0.29 4.99 ± 0.29
HDL-cholesterol (mM) 3.30 ± 0.24 3.34 ± 0.12 3.23 ± 0.16
LDL-cholesterol (mM) 29.6 ± 1.7 29.4 ± 0.9 26.8 ± 1.1
Cysteamine (μM) 0.0933 ± 0.034 0.251 ± 0.019 0.764 ± 0.071*
Aortic root (mm2)$ 0.487 ± 0.025 0.397 ± 0.029 0.397 ± 0.026
Aortic arch (%)# 35.0 ± 1.8 26.0 ± 1.2 27.0 ± 1.1
Thoracic + Abdominal (%) 2.29 ± 0.64 1.53 ± 0.32 1.36 ± 0.27
Body weight, plasma lipids, plasma cysteamine concentrations and atherosclerotic lesions in three aortic regions (mean ± SEM) were measured in mice fed a
Western diet with or without cysteamine for 12 weeks. ANOVA showed no significant difference in body weight and lipids between groups. Cysteamine con-
centrations in plasma were significantly higher in mice receiving the drug compared to the control group (p < 0.001, ANOVA), with the higher dose group having
higher plasma concentrations than the control or lower dose groups (*p < 0.0001, Tukey's post hoc test). The inhibition of the disease was not significantly affected
by dose at any of the three aortic locations examined, as assessed by either 2-way ANOVA (p=0.65) or t-test (p=0.93 for aortic root, p=0.57 for aortic arch and
p=0.69 for remaining thoracic plus abdominal aorta) and data for the two doses were therefore combined. The effect of cysteamine was significant in the aortic root
($p=0.010; t-test) and arch (#p=0.00001; t-test). It appeared to cause an even greater reduction in the descending aorta but the effect only approached statistical
significance (p=0.11), probably because the level of disease was low in these regions and the measurements were consequently highly variable.
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We tested if the lysosomal oxidation of SMase-LDL that had already
accumulated in lysosomes could be inhibited using antioxidants that
have access to lysosomes. BHT, which contains an antioxidant phenolic
hydroxyl group (Supplementary Fig. 5), inhibited the oxidation effec-
tively (Fig. 2G). The prodrug amifostine and its active product WR-
1065, which contains an antioxidant thiol group (Supplementary
Fig. 5), also inhibited the lysosomal oxidation of SMase-LDL effectively
(Fig. 2G). Amifostine protects normal tissues from damage caused by
radiation and chemotherapy [62]. WR-1065 protects macrophages
against death induced by hydrogen peroxide, which is mediated by
lysosomal redox active iron [62]. The prodrug amifostine would have to
be hydrolysed to WR-1065 before uptake, presumably by alkaline
phosphatase, which is present on human-monocyte-derived macro-
phages [63]. The active drug WR-1065 may diffuse into lysosomes and
then become protonated and trapped in these organelles, accumulating
to high concentrations, as do other lysosomotropic compounds.
Lysosomal oxidation of LDL in HMDM was also inhibited by the
lysosomotropic drug cysteamine (Fig. 3B and C), which was effective at
very low concentrations due to accumulation within lysosomes [28].
LDL oxidation by iron at lysosomal pH was also inhibited by cystea-
mine, with a greatly extended lag period (Fig. 3A).
Importantly, atherosclerosis in both the aortic root and arch of LDL
receptor-deficient mice on a Western diet was highly significantly re-
duced by cysteamine, in the absence of any changes in plasma lipo-
protein concentrations (Table 1). One possible mechanism by which
cysteamine protects against atherosclerosis is by inhibiting the lyso-
somal oxidation of LDL. The lower dose, equivalent to that given to
cystinosis patients [51], was as effective as the higher dose (Fig. 4),
presumably because the accumulation of cysteamine in lysosomes
meant that the lower dose was sufficient to inhibit effectively the oxi-
dation of LDL in these organelles. Cysteamine does not inhibit the ag-
gregation of LDL by sphingomyelinase (Supplementary Fig. 2) but
should inhibit the lysosomal oxidation of LDL. It might therefore have
more effects on the inflammatory and toxic effects of oxidised LDL than
on lipid accumulation in the arterial wall. We have recently shown that
cysteamine inhibits the secretion of pro-inflammatory cytokines from
macrophages incubated with SMase-LDL by inhibiting the lysosomal
oxidation of LDL [27].
These results support our hypothesis that the lysosomal oxidation of
LDL is a critical underlying cause of atherosclerosis and hence anti-
oxidant drugs that concentrate in lysosomes might well provide a novel
therapy for this disease. The rare lysosomal storage disorder cystinosis
is an inherited disease caused by the absence of functional cystinosin,
the ubiquitous lysosomal cystine transporter [64]. The consequent ac-
cumulation of cystine in the lysosomes of all cells in the body leads to
progressive dysfunction of multiple organs. Cysteamine reacts with
cystine to form the mixed disulfide of cysteamine and cysteine, which
can leave the lysosome via the lysine/arginine transport system [65].
The therapy, considered the only effective treatment for cystinosis,
prolongs the patients’ lives from about 10 years to as much as 40 years
[66]. Cysteamine may also be a potential treatment for neuronal ceroid
lipofuscinoses, a group of inherited progressive neurodegenerative
disorders [67]. Cysteamine is given to cystinosis patients orally several
times a day from childhood indefinitely. The plasma concentrations in
Fig. 4. Cysteamine reduced atherosclerosis in LDL receptor-deficient mice.
(A) Representative digital images to show atherosclerotic lesions in the aortic arch of control mice and mice treated with the lower dose of cysteamine (2.2mM in
drinking water). Scale bar: 2mm. Data points to show lesion areas in individual mice in each group in aortic root (B), aortic arch (C) and the remaining thoracic plus
abdominal aorta (D) of mice given the low (2.2 mM) and high doses (8.8 mM) of cysteamine. There were 19–22 mice in each group and the horizontal line shows the
group mean ± SEM. The combined effect of both doses of cysteamine was significant in the aortic root (p=0.010; t-test) and arch (p=0.00001; t-test) and was
significant for the lower dose alone (p < 0.001 ANOVA; p=0.0002 control vs. lower dose, Tukey's post hoc test) and the upper dose alone (p=0.001 control vs.
higher dose, Tukey's) for the aortic arch.
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patients are well above those needed in culture medium to inhibit ly-
sosomal LDL oxidation inside human macrophages, measured by the
formation of the advanced oxidation product ceroid (Fig. 3). The ef-
fectiveness of cysteamine at these extracellular concentrations may
reflect its accumulation in lysosomes. The most common adverse effects
of cysteamine [52] are gastrointestinal problems, which can be treated
by proton pump inhibitors, and unpleasant breath and sweat odour,
which might possibly be avoided by using prodrugs [68].
Arterial calcification is frequently a sequela of atherosclerosis. Our
hypothesis is therefore supported by the observation that there is a
striking inverse relationship between arterial calcification and the
number of years that cystinosis patients have been on cysteamine and a
striking positive relationship between arterial calcification and the
number of years that they have been off cysteamine [69]. A clinical trial
using cysteamine to try to prevent cardiovascular disease would be a far
better test of the oxidised LDL hypothesis of atherosclerosis than ones
using α-tocopherol, which is a far less effective antioxidant for LDL at
lysosomal pH than pH 7.4 [24].
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